Celularity makes cell therapy available in Florida under new state law
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
June 4, 2026 8:00 AM EDTFLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC (Fountain Life), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsible use of regenerative medicine.
This milestone marks the establishment of one of... More
